220 related articles for article (PubMed ID: 23081704)
1. The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.
Höfer P; Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Konstantinidis A; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):385-91. PubMed ID: 23081704
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients.
Serretti A; Calati R; Massat I; Linotte S; Kasper S; Lecrubier Y; Sens-Espel R; Bollen J; Zohar J; Berlo J; Lienard P; De Ronchi D; Mendlewicz J; Souery D
Int Clin Psychopharmacol; 2009 Sep; 24(5):250-6. PubMed ID: 19593158
[TBL] [Abstract][Full Text] [Related]
3. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study.
Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Papageorgiou K; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
Eur Neuropsychopharmacol; 2012 Apr; 22(4):259-66. PubMed ID: 21940152
[TBL] [Abstract][Full Text] [Related]
4. The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre study.
Höfer P; Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Konstantinidis A; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
Int Clin Psychopharmacol; 2016 Jan; 31(1):1-7. PubMed ID: 26544898
[TBL] [Abstract][Full Text] [Related]
5. Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression.
Carlberg L; Schosser A; Calati R; Serretti A; Massat I; Papageorgiou K; Kocabas NA; Mendlewicz J; Zohar J; Montgomery SA; Souery D; Kasper S
Int J Neurosci; 2015 May; 125(5):336-43. PubMed ID: 24955721
[TBL] [Abstract][Full Text] [Related]
6. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
7. The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study.
Schosser A; Carlberg L; Calati R; Serretti A; Massat I; Spindelegger C; Linotte S; Mendlewicz J; Souery D; Zohar J; Montgomery S; Kasper S
Int J Neuropsychopharmacol; 2017 Oct; 20(10):782-787. PubMed ID: 28977521
[TBL] [Abstract][Full Text] [Related]
8. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
13. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
[TBL] [Abstract][Full Text] [Related]
14. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Hall-Flavin DK; Winner JG; Allen JD; Carhart JM; Proctor B; Snyder KA; Drews MS; Eisterhold LL; Geske J; Mrazek DA
Pharmacogenet Genomics; 2013 Oct; 23(10):535-48. PubMed ID: 24018772
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
17. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
18. A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment.
Johnson M; Markham-Abedi C; Susce MT; Murray-Carmichael E; McCollum S; de Leon J
CNS Spectr; 2006 Oct; 11(10):757-60. PubMed ID: 17008819
[TBL] [Abstract][Full Text] [Related]
19. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder.
Pinna M; Manchia M; Pisanu C; Pinna F; Paribello P; Carta A; Meloni A; Conversano C; Del Zompo M; Mola F; Squassina A; Carpiniello B
Psychiatr Genet; 2021 Oct; 31(5):186-193. PubMed ID: 34282075
[TBL] [Abstract][Full Text] [Related]
20. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
